{"gene":"S100A4","run_date":"2026-06-10T07:46:28","timeline":{"discoveries":[{"year":1994,"finding":"S100A4 (pEL98) binds nonmuscle tropomyosin isoform 2 (TM2) in a Ca2+-dependent manner; the binding site was mapped to residues 39–107 on TM2, and some S100A4 co-localizes with nonmuscle tropomyosins in microfilament bundles of NIH 3T3 cells.","method":"GST pulldown with Ca2+-dependence assay, competition with free TM2, affinity chromatography, partial amino acid sequencing, immunofluorescence co-localization, cell fractionation (Triton-soluble vs. insoluble)","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with multiple orthogonal methods (pulldown, competition, fractionation, immunofluorescence) in a single rigorous study","pmids":["8120097"],"is_preprint":false},{"year":1994,"finding":"Recombinant rat S100A4 (p9Ka) forms multimers in vitro (not via disulfide bonds), binds 2 mol Ca2+/mol protein (antagonized by mono- and divalent cations), and binds to at least two intracellular polypeptides in mammary cell extracts. Immunofluorescence shows co-localization with actin filaments.","method":"Recombinant protein characterization, equilibrium dialysis, gel overlay / affinity binding assay, immunofluorescence","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with multiple methods (biochemical binding, Ca2+ measurement, immunofluorescence) in one rigorous study","pmids":["8034656"],"is_preprint":false},{"year":1992,"finding":"S100A4 (calvasculin) is secreted by smooth muscle cells and fibroblasts in culture and binds the extracellular 36-kDa microfibril-associated glycoprotein (MAP) in a Ca2+-dependent manner; stoichiometry ~2.2 calvasculin/mol MAP.","method":"Immunofluorescence demonstrating granular (secretory) distribution, Ca2+-dependent solid-phase binding assay, stoichiometry analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct secretion demonstrated by immunofluorescence, binding confirmed by solid-phase assay with Ca2+ dependence, single lab","pmids":["1512251"],"is_preprint":false},{"year":1994,"finding":"S100A4 (pEL98) expression level correlates with and is sufficient to promote cell motility and tumor cell invasiveness; transfection of pEL98 cDNA into low-motility cells directly increases motility.","method":"phagokinesis cell-track assay, cDNA transfection overexpression, Northern/Western blot correlation across cell lines","journal":"Japanese journal of cancer research : Gann","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function transfection with defined phenotypic readout (motility), supported by correlation across multiple cell lines, single lab","pmids":["7928629"],"is_preprint":false},{"year":1998,"finding":"Human S100A4 possesses metastasis-inducing capability: transfection into benign rat mammary Rama 37 cells induced metastasis in vivo only in clones expressing high levels of human S100A4, not in clones with undetectable expression.","method":"Gene transfection, in vivo metastasis assay in syngeneic rats, immunocytochemistry","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — gain-of-function in vivo assay replicated across multiple clones with dose-response relationship; confirms earlier rodent studies","pmids":["9696040"],"is_preprint":false},{"year":1996,"finding":"Expression of S100A4 in MMTV-neu transgenic mice cooperates with the Neu oncogene to induce macroscopic lung metastases; primary and secondary lesions express S100A4, particularly at invasion fronts.","method":"Transgenic mouse cross (MMTV-neu × S100A4 transgenic), macroscopic metastasis assessment, immunohistochemistry","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo transgenic gain-of-function demonstrating metastasis induction cooperating with an oncogene, histological verification","pmids":["8895508"],"is_preprint":false},{"year":1996,"finding":"Ribozyme-mediated knockdown of S100A4 (CAPL) reduces metastatic skeletal colonization of human osteosarcoma cells in vivo without affecting proliferation or tumorigenicity, establishing S100A4 as a direct determinant of metastatic potential.","method":"Hammerhead ribozyme transfection, 5'-RACE cleavage assay, intracardiac injection metastasis model in nude rats, in vivo/in vitro proliferation assays","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — loss-of-function with verified mRNA cleavage, in vivo metastasis phenotype, proliferation controlled, single lab","pmids":["8968106"],"is_preprint":false},{"year":2001,"finding":"S100A4 binds nonmuscle myosin and p53 (wild-type and mutant arg-175-his) with significant affinity by optical biosensor measurement; S100A4 shows greater affinity for p53 than for myosin. S100A4 does not interact with actin, tropomyosin, or tubulin under these conditions.","method":"Optical biosensor (surface plasmon resonance) binding assay with recombinant proteins","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct in vitro binding measurement with affinity quantification; negative controls (actin, tropomyosin, tubulin) included; single lab, single method","pmids":["11527429"],"is_preprint":false},{"year":2000,"finding":"S100A4 interacts with S100A1 in vivo (detected by FRET in living cells) and in vitro (affinity chromatography, gel overlay); interaction is abolished by mutagenesis of conserved dimerization residues. S100A1 modulates S100A4's inhibition of nonmuscle myosin-A self-association and phosphorylation, reduces S100A4-induced motility and growth in soft agar, and attenuates metastasis in vivo.","method":"Yeast two-hybrid, site-directed mutagenesis, affinity chromatography, gel overlay, FRET in living cells, biosensor binding assay, in vitro myosin assay, soft agar assay, in vivo metastasis model","journal":"The Journal of biological chemistry / Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods (yeast two-hybrid, mutagenesis, FRET, in vitro myosin assay, in vivo) across two papers from the same lab","pmids":["10753920","15608682"],"is_preprint":false},{"year":1994,"finding":"S100A4 (calvasculin/CAPL) is a homodimeric Ca2+-binding protein with two low-affinity Ca2+-specific sites per homodimer (K0.5 ~0.15 mM, slightly cooperative); it does not form heterodimers with S100B (CACY) in vitro, and Ca2+ binding induces conformational changes.","method":"Recombinant protein expression/purification, equilibrium dialysis (flow dialysis), fluorescence spectroscopy","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — rigorous biochemical characterization of Ca2+-binding stoichiometry and cooperativity; single lab with multiple methods","pmids":["8204608"],"is_preprint":false},{"year":2005,"finding":"Serotonin (5-HT) elevates S100A4 mRNA and protein in human pulmonary artery smooth muscle cells via 5-HT1B receptor and SERT, requiring pERK1/2 nuclear translocation (dependent on SERT, MAO activity, and ROS) and subsequent pGATA-4-mediated transcription; secreted S100A4 then stimulates HPASMC proliferation and migration through RAGE.","method":"Cell culture, pharmacological inhibition (SB224289, fluoxetine), siRNA knockdown of SERT, qPCR, ELISA, proliferation/migration assays","journal":"Circulation research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic dissection of transcriptional pathway with multiple pharmacological inhibitors and siRNA, single lab","pmids":["16002749"],"is_preprint":false},{"year":2007,"finding":"S100A4 protein is upregulated in hypertrophic and infarcted rat and human hearts; recombinant S100A4 elicits hypertrophic response and promotes survival (anti-apoptotic) in cardiac myocyte cultures, with ERK1/2 activation required for both hypertrophy and survival effects.","method":"qRT-PCR, immunoblotting, confocal microscopy/fractionation, recombinant protein treatment, ERK1/2 inhibition, viability assays","journal":"Cardiovascular research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro recombinant protein treatment with pathway inhibition, confirmed by human/rat tissue localization; single lab","pmids":["17466960"],"is_preprint":false},{"year":2010,"finding":"S100A4 is required for macrophage chemotaxis and recruitment to inflammation sites in vivo; S100A4-deficient bone marrow macrophages form unstable protrusions, overassemble myosin-IIA, and exhibit altered CSF-1 receptor signaling.","method":"S100A4 gene-targeted knockout mice, in vivo peritoneal recruitment assay, in vitro chemotaxis assay, myosin assembly analysis, receptor signaling assays","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean knockout model with defined in vivo and in vitro phenotypes, mechanistic link to myosin-IIA overassembly and CSF-1R signaling","pmids":["20519440"],"is_preprint":false},{"year":2017,"finding":"S100A4 regulates macrophage invasion through two mechanistically distinct pathways: (1) a myosin-IIA-dependent defect in podosome rosette-mediated matrix degradation and (2) a myosin-independent increase in microtubule acetylation that increases podosome rosette stability and inhibits invasion.","method":"S100A4-/- bone marrow macrophages, podosome rosette imaging, matrix degradation assay, myosin-IIA manipulation, microtubule acetylation measurement","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — mechanistically resolved two independent pathways using S100A4-/- cells with multiple orthogonal readouts; replication from same group extending prior knockout study","pmids":["29282275"],"is_preprint":false},{"year":2010,"finding":"S100A4 physically and functionally interacts with Smad3 in a Ca2+-dependent manner; the S100A4-binding site is in the N-terminal region of Smad3. S100A4 potentiates Smad3 (and Smad2) transcriptional activity and increases TGF-β-induced MMP-9 expression and cell invasion; siRNA depletion reverses these effects.","method":"Co-immunoprecipitation, Ca2+-dependence assay, reporter assay for Smad transcriptional activity, siRNA knockdown, MMP-9 ELISA, Boyden chamber invasion assay","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with Ca2+-dependence plus functional gain/loss-of-function validation, single lab","pmids":["20070253"],"is_preprint":false},{"year":2017,"finding":"In IPF mesenchymal progenitor cells, nuclear S100A4 interacts with L-isoaspartyl methyltransferase to promote p53 degradation and MPC self-renewal; S100A4 gain-of-function confers fibrogenic properties to non-IPF MPCs, and S100A4 is required for conversion of a self-limited to persistent bleomycin fibrosis model in vivo.","method":"Ex vivo analysis of IPF MPCs, co-IP of S100A4 with L-isoaspartyl methyltransferase, p53 degradation assay, S100A4 overexpression in non-IPF MPCs, in vivo bleomycin mouse model with human MPC injection","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Moderate — Co-IP identifying interaction partner, in vivo loss- and gain-of-function, multiple orthogonal methods in single rigorous study","pmids":["28530639"],"is_preprint":false},{"year":2018,"finding":"Extracellular S100A4 inhibits autophagy and promotes tumor cell proliferation via RAGE receptor, acting through the Wnt/β-catenin pathway; RAGE-specific inhibition abolishes S100A4-mediated autophagy suppression. S100A4-deficient mice show retarded lung tumor development with increased autophagy markers.","method":"S100A4 overexpression/siRNA knockdown, autophagy markers (LC3-II), β-catenin measurement, RAGE inhibitor (FPS-ZM1), S100A4-/- mouse tumor model","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway dissected with pharmacological RAGE inhibition and KO mice plus in vitro gain/loss-of-function; single lab","pmids":["29449540"],"is_preprint":false},{"year":2018,"finding":"S100A4 protects myeloid-derived suppressor cells from intrinsic apoptosis via TLR4/ERK1/2 signaling-dependent caspase-9 inhibition; S100A4-/- mice have reduced peripheral MDSCs and spontaneously reject tumors.","method":"S100A4-/- tumor models, MDSC isolation and apoptosis assays, TLR4 and ERK1/2 pathway analysis, caspase-9 activity measurement","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined molecular pathway (TLR4-ERK1/2-caspase-9) in KO model with tumor model phenotype, single lab","pmids":["29556233"],"is_preprint":false},{"year":2021,"finding":"S100A4 controls PPAR-γ upregulation in macrophages, which is required for FAO induction during M2-like protumor polarization; S100A4-deficient TAMs fail to upregulate PPAR-γ-dependent CD36, reducing FA absorption and FAO, and thereby lose protumor activity.","method":"Macrophage-specific S100A4-KO mice, whole-body KO mice, IL-4 stimulation, RNA-seq, flow cytometry, Western blot, FAO measurement, FA uptake assay","journal":"Journal for immunotherapy of cancer","confidence":"High","confidence_rationale":"Tier 2 / Strong — mechanistic pathway (S100A4→PPAR-γ→CD36→FAO) established with cell-specific KO, multiple metabolic and molecular readouts, in vivo tumor models","pmids":["34145030"],"is_preprint":false},{"year":2021,"finding":"Exosomal S100A4 from highly metastatic HCC cells activates STAT3 phosphorylation in recipient low-metastatic cells, inducing osteopontin (OPN) transcription and promoting metastasis in vitro and in vivo.","method":"Exosome isolation, iTRAQ mass spectrometry, in vitro invasion/migration assays, xenograft in vivo metastasis, STAT3 phosphorylation assay, OPN promoter analysis","journal":"Signal transduction and targeted therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic pathway (exosomal S100A4→STAT3 phosphorylation→OPN) validated in vitro and in vivo, single lab","pmids":["34035222"],"is_preprint":false},{"year":2022,"finding":"S100A4 interacts with Smad3 to stabilize the Smad3/Smad4 complex and promote their nuclear translocation, thereby facilitating TGF-β1-induced fibroblast activation; pharmacological inhibition with niclosamide reduces this interaction and attenuates renal fibrosis in vivo.","method":"Co-IP (S100A4–Smad3 interaction), Smad3/Smad4 complex stability assay, nuclear translocation assay, S100A4 overexpression/knockdown in renal fibroblasts, folic acid nephropathy mouse model, niclosamide treatment","journal":"Cells","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — Co-IP identifying specific molecular interaction, mechanistic nuclear translocation assay, gain/loss-of-function, in vivo model; single lab with multiple orthogonal methods","pmids":["36078170"],"is_preprint":false},{"year":2022,"finding":"Extracellular oligomeric S100A4 induces NF-κB activation and, together with PDGF-BB, drives smooth muscle cell phenotypic transition to a pro-inflammatory synthetic phenotype via toll-like receptor-4; neutralization of extracellular S100A4 in a mouse atherosclerosis model decreases plaque area, necrotic core, and macrophage content while increasing contractile markers.","method":"Recombinant oligomeric S100A4 treatment of SMCs, NF-κB reporter assay, RNA-seq, TLR4 signaling assay, ApoE-/- atherosclerosis mouse model with neutralizing antibody","journal":"Cardiovascular research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — mechanistic pathway (oS100A4→TLR4→NF-κB→phenotype transition) established with RNA-seq and in vivo neutralization; multiple methods, single lab","pmids":["33135065"],"is_preprint":false},{"year":2018,"finding":"S100A4 neuroprotection involves signaling through ErbB4 and its ligand Neuregulin-1: neuroprotective effect requires ErbB4 expression and ErbB2/Akt signaling, and is reduced by functional blockade of NRG/ErbB4. S100A4 also binds ErbB1 (EGFR) and ErbB3.","method":"ErbB4 knockdown/overexpression, pharmacological ErbB blockade, binding assays, primary and immortalized dopaminergic neuron cell death models","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined receptor pathway with genetic (knockdown) and pharmacological validation; binding to ErbB1/ErbB3 shown; single lab","pmids":["30083275"],"is_preprint":false},{"year":2016,"finding":"S100A4 elevation in Drosophila promotes metastatic dissemination of RasV12-induced tumors via activation of the stress kinase JNK and upregulation of MMP1; genetic and chemical blockade of JNK or MMP1 suppresses S100A4-mediated metastasis in this model.","method":"Drosophila genetic model (RasV12 + S100A4 overexpression), JNK reporter assay, MMP1 measurement, genetic epistasis (loss-of-function of JNK and MMP1)","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis in a model organism with pathway placement (JNK–MMP1); single lab","pmids":["27927689"],"is_preprint":false},{"year":2013,"finding":"S100A4 deficiency increases trabecular and cortical bone mass in mice; S100A4-deficient osteoclasts are small with few nuclei and pseudopodial processes, have low surface integrins, poor adhesion capacity, impaired multinucleation, and low cathepsin K and MMP3/MMP9 content, indicating S100A4 is required for functional osteoclastogenesis and bone resorption.","method":"S100A4-KO mice, shRNA lentiviral knockdown, pQCT, histomorphometry, TRAP staining, osteoclast differentiation assay, integrin surface expression","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 2 / Strong — two independent loss-of-function approaches (KO and shRNA) with defined cellular and molecular phenotypes; multiple orthogonal readouts","pmids":["23830916"],"is_preprint":false},{"year":2019,"finding":"S100A4 drives fibrotic tendon healing primarily through a cell non-autonomous (paracrine/secreted) mechanism; S100A4 haploinsufficiency decreases myofibroblast and macrophage content at injury sites; S100a4-lineage cells become α-SMA+ myofibroblasts via loss of S100a4 expression; antagonism of its putative receptor RAGE also decreases scar formation.","method":"S100a4 haploinsufficient mice, lineage tracing (S100a4-Cre), RAGE antagonist treatment, immunofluorescence quantification of myofibroblasts and macrophages, biomechanical tendon testing","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 / Strong — combination of genetic mouse models (haploinsufficiency + lineage tracing), small molecule inhibition, and functional biomechanical readout","pmids":["31124787"],"is_preprint":false},{"year":2014,"finding":"NFAT5 transcriptionally induces S100A4 expression in renal carcinoma cells; siRNA-mediated knockdown of NFAT5 reduces S100A4 levels and is accompanied by decreased proliferation and migration of CaKi-1 cells.","method":"NFAT5 siRNA knockdown, reporter assay for NFAT5 activity, qPCR for S100A4, proliferation and migration assays","journal":"Frontiers in physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — siRNA loss-of-function with clear transcriptional link; single lab, single method for the S100A4 regulatory relationship","pmids":["25152734"],"is_preprint":false},{"year":2016,"finding":"S100A4 protects cardiac myocytes against ischemic injury; cardiac myocyte-specific overexpression protects infarcted myocardium, while S100A4 KO worsens outcomes with increased apoptosis, fibrosis, and reduced capillary density. S100A4 promotes survival through AKT signaling and VEGF expression.","method":"S100A4 KO mice, cardiac myocyte-specific S100A4 overexpression transgenic mice, myocardial infarction model, apoptosis assays, Western blot (AKT phosphorylation), VEGF measurement","journal":"Journal of molecular and cellular cardiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal KO and tissue-specific overexpression with defined molecular mechanism (AKT/VEGF), multiple orthogonal readouts","pmids":["27721024"],"is_preprint":false},{"year":1997,"finding":"A GC-factor binding sequence ~1,300 bp upstream of the S100A4 transcription start site acts as a cis-acting transcriptional repressor in benign mammary cells (low S100A4) but not in malignant/metastatic cells (high S100A4); GC-factor mRNA levels are inversely correlated with S100A4 mRNA across mammary cell lines.","method":"Reporter gene assay, Northern blot correlation across cell lines, identification of cis-acting element","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assay with defined cis-element plus mRNA correlation across cell lines; single lab","pmids":["9242709"],"is_preprint":false},{"year":2007,"finding":"Nuclear (but not cytoplasmic) expression of S100A4 in cholangiocarcinoma cells increases invasiveness and metastasization; siRNA silencing of S100A4 reduces motility, invasiveness, and MMP-9 secretion without affecting proliferation in EGI-1 CCA cells.","method":"siRNA knockdown, wound healing assay, Boyden chamber invasion assay, MMP-9 zymography, xenotransplantation in SCID mice with luciferase imaging, immunohistochemistry","journal":"Hepatology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — loss-of-function (siRNA) with multiple functional readouts and in vivo xenograft validation, nuclear localization mechanistically specified","pmids":["21618579"],"is_preprint":false},{"year":2016,"finding":"Extracellular S100A4 interacts with RAGE on endothelial cells to reduce endothelial integrity (decreased TEER, reduced occludin and VE-cadherin expression) and facilitates transmigration of melanoma cells; this prometastatic effect is reduced by soluble RAGE (sRAGE).","method":"TEER measurement, Western blot for junction proteins, RAGE inhibition with sRAGE, transgenic A375 cell transmigration assay, intracardiac mouse metastasis model","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional RAGE-dependence established with sRAGE inhibition and in vivo model; single lab","pmids":["27387233"],"is_preprint":false},{"year":2011,"finding":"S100A4 co-immunoprecipitates with RAGE in diabetic rat retinas; TNF-α (but not VEGF) induces upregulation of S100A4 in human retinal microvascular endothelial cells.","method":"Co-immunoprecipitation, Western blot, ELISA, immunohistochemistry, in vitro cytokine stimulation","journal":"Molecular vision","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single Co-IP in tissue extract, single lab, limited mechanistic follow-up","pmids":["25253987"],"is_preprint":false},{"year":1998,"finding":"S100A4 modulates expression of matrix metalloproteinases (MMPs) and TIMPs in osteosarcoma cells: high-CAPL-expressing cells fail to upregulate MMP-1 and MMP-9 in response to bFGF or IL-1α, and high CAPL in synergy with IL-1α reduces TIMP-1 synthesis.","method":"Ribozyme-mediated CAPL knockdown cell lines, ELISA for MMP/TIMP levels, gelatin zymography, growth factor/cytokine stimulation","journal":"Anticancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — defined MMP/TIMP regulatory phenotype using loss-of-function cells with cytokine stimulation; single lab","pmids":["9858899"],"is_preprint":false},{"year":2020,"finding":"S100A4 promotes hepatocellular carcinoma stemness synergistically with collagen I via RAGE and β-catenin signaling; this synergy requires both S100A4 and collagen I for maximal tumor sphere formation in vitro and tumor growth in vivo.","method":"S100A4-/- mouse hepatocarcinogenesis model (DEN/CCl4), tumor sphere formation assay, RAGE inhibition, β-catenin pathway analysis, in vivo tumor growth","journal":"Oncoimmunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined cooperative mechanism with extracellular matrix and receptor (RAGE/β-catenin) in KO model plus in vitro; single lab","pmids":["32117590"],"is_preprint":false}],"current_model":"S100A4 is a dimeric, Ca2+-binding EF-hand protein that operates both intracellularly—binding nonmuscle myosin-IIA, p53, Smad3, S100A1, and tropomyosin to regulate cell motility, cytoskeletal dynamics, apoptosis, and transcription—and extracellularly after secretion, where it signals through RAGE and TLR4 to activate NF-κB, promote SMC phenotypic transition, stimulate angiogenesis, and drive fibrosis and metastasis across multiple tissue contexts."},"narrative":{"mechanistic_narrative":"S100A4 is a small, homodimeric EF-hand protein that binds two Ca2+ ions per monomer with low affinity and cooperativity, undergoing a Ca2+-induced conformational change but not heterodimerizing with S100B [PMID:8204608, PMID:8034656]. Intracellularly, it acts on the cytoskeleton through Ca2+-dependent association with nonmuscle tropomyosin and with nonmuscle myosin-IIA, with which it co-localizes in microfilament structures [PMID:8120097, PMID:11527429]; binding to myosin-IIA limits filament self-assembly, and this activity is modulated by heterocomplex formation with S100A1 [PMID:10753920, PMID:15608682]. Through control of myosin-IIA dynamics S100A4 governs cell motility and protrusion stability, driving macrophage chemotaxis, podosome-mediated matrix degradation, and invasion [PMID:7928629, PMID:20519440, PMID:29282275]. S100A4 is a direct determinant of metastatic potential: gain-of-function transfection induces metastasis and cooperates with the Neu oncogene in vivo, while ribozyme or siRNA depletion suppresses metastatic colonization and MMP-9-dependent invasion [PMID:9696040, PMID:8895508, PMID:8968106, PMID:21618579]. It additionally functions as a nuclear and transcriptional cofactor, binding p53 and the L-isoaspartyl methyltransferase to promote p53 degradation, and binding Smad3 in a Ca2+-dependent manner to stabilize the Smad3/Smad4 complex, potentiate TGF-β signaling, and drive fibroblast activation and fibrosis [PMID:11527429, PMID:28530639, PMID:20070253, PMID:36078170]. Upon secretion, extracellular S100A4 signals chiefly through the RAGE and TLR4 receptors to activate NF-κB, STAT3, AKT, ERK1/2, and Wnt/β-catenin pathways, thereby promoting smooth muscle phenotypic transition, angiogenesis, autophagy suppression, cell survival, and tissue fibrosis across vascular, cardiac, pulmonary, renal, and tendon contexts [PMID:33135065, PMID:29449540, PMID:34035222, PMID:27721024, PMID:31124787, PMID:16002749]. Its expression is set by transcriptional inputs including a GC-factor repressor element, NFAT5, and serotonin-driven GATA-4 signaling [PMID:9242709, PMID:25152734, PMID:16002749].","teleology":[{"year":1992,"claim":"Establishing that S100A4 is actively secreted answered whether this intracellular protein has an extracellular life, opening the door to receptor-mediated signaling models.","evidence":"Immunofluorescence of secretory distribution and Ca2+-dependent solid-phase binding to microfibril-associated glycoprotein in smooth muscle cells and fibroblasts","pmids":["1512251"],"confidence":"Medium","gaps":["No receptor identified at this stage","Functional consequence of secretion not addressed"]},{"year":1994,"claim":"Biochemical characterization defined S100A4 as a low-affinity Ca2+-binding homodimer that does not heterodimerize with S100B, establishing it as a distinct Ca2+ sensor whose targets change with Ca2+ occupancy.","evidence":"Recombinant protein, equilibrium/flow dialysis, fluorescence spectroscopy, multimerization analysis","pmids":["8204608","8034656"],"confidence":"High","gaps":["Physiological Ca2+ thresholds in cells unresolved","Identity of intracellular target polypeptides not defined here"]},{"year":1994,"claim":"Identifying tropomyosin and actin co-localization gave the first cytoskeletal targets, framing S100A4 as a Ca2+-dependent regulator of the actomyosin system.","evidence":"GST pulldown with mapped TM2 binding site, competition, fractionation, and immunofluorescence in NIH 3T3 cells","pmids":["8120097","8034656"],"confidence":"High","gaps":["Functional effect of tropomyosin binding on filaments untested","Later SPR found no direct actin/tropomyosin binding, indicating context dependence"]},{"year":1994,"claim":"Demonstrating that S100A4 expression is sufficient to promote motility connected the cytoskeletal binding activity to a metastasis-relevant phenotype.","evidence":"Phagokinesis track assay with cDNA overexpression and cross-cell-line correlation","pmids":["7928629"],"confidence":"Medium","gaps":["Molecular intermediary between S100A4 and motility not defined","In vivo relevance not yet tested"]},{"year":1998,"claim":"In vivo transfection and oncogene-cooperation studies established S100A4 as a causal metastasis-inducing gene rather than a correlate.","evidence":"Gene transfection into benign rat mammary cells with dose-dependent in vivo metastasis; MMTV-neu transgenic cross","pmids":["9696040","8895508","8968106"],"confidence":"High","gaps":["Mechanism distinguishing high- vs low-expressing clones unresolved","Did not separate intracellular from secreted contributions"]},{"year":2001,"claim":"Direct affinity measurements identified myosin and p53 as preferred S100A4 partners, shifting the model toward both cytoskeletal and transcriptional/apoptotic regulation.","evidence":"Surface plasmon resonance with recombinant proteins and negative controls (actin, tropomyosin, tubulin)","pmids":["11527429"],"confidence":"Medium","gaps":["Cellular consequence of p53 binding not addressed","Discrepancy with earlier tropomyosin/actin binding unexplained"]},{"year":2000,"claim":"Discovering the S100A4–S100A1 heterocomplex revealed an endogenous brake on S100A4's myosin-modulating and metastatic activities.","evidence":"Yeast two-hybrid, dimerization-residue mutagenesis, FRET in living cells, in vitro myosin assay, soft agar and in vivo metastasis assays","pmids":["10753920","15608682"],"confidence":"High","gaps":["Regulation of heterocomplex formation in vivo unknown","Stoichiometry in cells not defined"]},{"year":2005,"claim":"Defining the serotonin/5-HT1B/SERT/ERK/GATA-4 axis explained how S100A4 transcription is induced and linked it to autocrine RAGE signaling in pulmonary vascular cells.","evidence":"Pharmacological inhibition, SERT siRNA, qPCR, ELISA, proliferation/migration assays in HPASMCs","pmids":["16002749"],"confidence":"Medium","gaps":["Direct GATA-4 binding to the S100A4 promoter not shown","RAGE engagement inferred pharmacologically"]},{"year":2010,"claim":"Knockout macrophage studies mechanistically tied S100A4 loss to myosin-IIA overassembly and defective chemotaxis, grounding its motility role in a defined cell type and target.","evidence":"S100A4-/- bone marrow macrophages, in vivo recruitment, chemotaxis and myosin assembly assays","pmids":["20519440"],"confidence":"High","gaps":["CSF-1R signaling alteration mechanism incomplete","Intracellular vs secreted contribution to recruitment not separated"]},{"year":2010,"claim":"Identification of Ca2+-dependent Smad3 binding established S100A4 as a TGF-β pathway amplifier driving MMP-9 expression and invasion.","evidence":"Co-IP with Ca2+-dependence, Smad reporter assays, siRNA, MMP-9 ELISA, Boyden chamber invasion","pmids":["20070253"],"confidence":"Medium","gaps":["Structural basis of Smad3 N-terminal binding not resolved","Single-lab Co-IP without reciprocal genetic validation"]},{"year":2013,"claim":"Bone phenotyping showed S100A4 is required for functional osteoclastogenesis, extending its motility/adhesion role to physiological bone remodeling.","evidence":"S100A4-KO mice and shRNA knockdown with pQCT, histomorphometry, TRAP and differentiation assays","pmids":["23830916"],"confidence":"High","gaps":["Whether effect is intracellular or secreted not resolved","Receptor mediating osteoclast effects not identified"]},{"year":2016,"claim":"Cross-species and cardiac/endothelial studies placed S100A4 in stress-kinase and survival signaling, defining MMP1/JNK, AKT/VEGF, and RAGE-dependent barrier disruption as downstream effectors.","evidence":"Drosophila JNK/MMP1 epistasis; cardiac KO and myocyte-specific overexpression with MI models; endothelial TEER and sRAGE inhibition with intracardiac metastasis","pmids":["27927689","27721024","27387233"],"confidence":"High","gaps":["Context-specific switch between pro-survival and pro-metastatic outputs unexplained","Receptor coupling to AKT vs JNK not unified"]},{"year":2017,"claim":"Resolving two independent macrophage invasion pathways and a nuclear S100A4–methyltransferase–p53 axis clarified that S100A4 acts through both myosin-dependent and myosin-independent and nuclear mechanisms.","evidence":"S100A4-/- macrophage podosome and microtubule acetylation assays; IPF MPC co-IP with L-isoaspartyl methyltransferase, p53 degradation, gain-of-function, bleomycin in vivo model","pmids":["29282275","28530639"],"confidence":"High","gaps":["How microtubule acetylation is controlled by S100A4 mechanistically unknown","Direct enzymatic link between the methyltransferase and p53 stability not fully defined"]},{"year":2018,"claim":"Receptor-resolved studies established RAGE/Wnt-β-catenin, TLR4/ERK/caspase-9, and NRG/ErbB4 as distinct extracellular S100A4 signaling routes controlling autophagy, immune-cell survival, and neuroprotection.","evidence":"RAGE inhibitor (FPS-ZM1) and KO autophagy tumor model; TLR4/ERK1/2 MDSC apoptosis in KO mice; ErbB4 knockdown/blockade in dopaminergic neuron models","pmids":["29449540","29556233","30083275"],"confidence":"Medium","gaps":["Which receptor dominates in a given tissue not defined","Binding affinities to ErbB1/3/4 not quantified relative to RAGE/TLR4"]},{"year":2022,"claim":"Mechanistic dissection in fibrosis, atherosclerosis, and HCC unified S100A4's secreted role: oligomeric S100A4 signals via TLR4/NF-κB and RAGE to drive SMC phenotype switching, fibroblast activation through Smad3/Smad4 stabilization, and metastatic niche formation via exosomal STAT3/OPN.","evidence":"Oligomeric S100A4 + PDGF-BB on SMCs with NF-κB reporter and ApoE-/- neutralization; S100A4–Smad3 Co-IP with niclosamide in folic-acid nephropathy; exosomal S100A4 STAT3/OPN in HCC xenografts","pmids":["33135065","36078170","34035222","34145030"],"confidence":"High","gaps":["Oligomeric state required for receptor engagement in vivo not fully defined","Whether the same secreted pool drives Smad3 stabilization and TLR4 signaling unknown"]},{"year":null,"claim":"It remains unresolved how a single Ca2+-binding protein partitions between distinct intracellular partners (myosin-IIA, p53, Smad3) and multiple extracellular receptors (RAGE, TLR4, ErbB family) to produce context-specific outcomes.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural model reconciling diverse partner binding to the dimer","Mechanism and regulation of S100A4 secretion not defined","Receptor selectivity by oligomeric state untested side by side"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[0,7,8,12]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[14,15,20]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[8,14,20]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[21,16,30]}],"localization":[{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[0,1]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[15,29]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[2,21,25]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[12,7]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[21,16,19,27]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[4,5,6,15,25]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[12,17,18]},{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[14,29,32]}],"complexes":[],"partners":["MYH9","TPM2","TP53","SMAD3","S100A1","AGER","TLR4","ERBB4"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P26447","full_name":"Protein S100-A4","aliases":["Calvasculin","Metastasin","Placental calcium-binding protein","Protein Mts1","S100 calcium-binding protein A4"],"length_aa":101,"mass_kda":11.7,"function":"Calcium-binding protein that plays a role in various cellular processes including motility, angiogenesis, cell differentiation, apoptosis, and autophagy (PubMed:16707441, PubMed:23752197, PubMed:30713770). Increases cell motility and invasiveness by interacting with non-muscle myosin heavy chain (NMMHC) IIA/MYH9 (PubMed:16707441). Mechanistically, promotes filament depolymerization and increases the amount of soluble myosin-IIA, resulting in the formation of stable protrusions facilitating chemotaxis (By similarity). Also modulates the pro-apoptotic function of TP53 by binding to its C-terminal transactivation domain within the nucleus and reducing its protein levels (PubMed:23752197). Within the extracellular space, stimulates cytokine production including granulocyte colony-stimulating factor and CCL24 from T-lymphocytes (By similarity). In addition, stimulates T-lymphocyte chemotaxis by acting as a chemoattractant complex with PGLYRP1 that promotes lymphocyte migration via CCR5 and CXCR3 receptors (PubMed:26654597, PubMed:30713770)","subcellular_location":"Secreted; Nucleus; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P26447/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/S100A4","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/S100A4","total_profiled":1310},"omim":[{"mim_id":"603348","title":"HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; HIF1A","url":"https://www.omim.org/entry/603348"},{"mim_id":"191170","title":"TUMOR PROTEIN p53; TP53","url":"https://www.omim.org/entry/191170"},{"mim_id":"176993","title":"S100 CALCIUM-BINDING PROTEIN A2; S100A2","url":"https://www.omim.org/entry/176993"},{"mim_id":"176992","title":"S100 CALCIUM-BINDING PROTEIN A3; S100A3","url":"https://www.omim.org/entry/176992"},{"mim_id":"176991","title":"S100 CALCIUM-BINDING PROTEIN A5; S100A5","url":"https://www.omim.org/entry/176991"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"blood vessel","ntpm":2003.6}],"url":"https://www.proteinatlas.org/search/S100A4"},"hgnc":{"alias_symbol":["P9KA","18A2","PEL98","42A","FSP1"],"prev_symbol":["MTS1","CAPL"]},"alphafold":{"accession":"P26447","domains":[{"cath_id":"1.10.238.10","chopping":"30-42_50-84","consensus_level":"medium","plddt":92.1992,"start":30,"end":84}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P26447","model_url":"https://alphafold.ebi.ac.uk/files/AF-P26447-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P26447-F1-predicted_aligned_error_v6.png","plddt_mean":86.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=S100A4","jax_strain_url":"https://www.jax.org/strain/search?query=S100A4"},"sequence":{"accession":"P26447","fasta_url":"https://rest.uniprot.org/uniprotkb/P26447.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P26447/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P26447"}},"corpus_meta":[{"pmid":"35140215","id":"PMC_35140215","title":"Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35140215","citation_count":383,"is_preprint":false},{"pmid":"20019188","id":"PMC_20019188","title":"S100A4 and metastasis: a small actor playing many roles.","date":"2009","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/20019188","citation_count":362,"is_preprint":false},{"pmid":"35122040","id":"PMC_35122040","title":"Cancer-associated fibroblast compositions change with breast cancer progression linking the ratio of S100A4+ and PDPN+ CAFs to clinical outcome.","date":"2020","source":"Nature cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35122040","citation_count":265,"is_preprint":false},{"pmid":"34145030","id":"PMC_34145030","title":"S100A4 enhances protumor macrophage polarization by control of PPAR-γ-dependent induction of fatty acid oxidation.","date":"2021","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34145030","citation_count":209,"is_preprint":false},{"pmid":"15900299","id":"PMC_15900299","title":"The metastasis associated protein S100A4: role in tumour progression and metastasis.","date":"2005","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15900299","citation_count":201,"is_preprint":false},{"pmid":"8895508","id":"PMC_8895508","title":"Expression of the calcium-binding protein S100A4 (p9Ka) in MMTV-neu transgenic mice induces metastasis of mammary tumours.","date":"1996","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/8895508","citation_count":176,"is_preprint":false},{"pmid":"11106237","id":"PMC_11106237","title":"Inverse expression of S100A4 and E-cadherin is associated with metastatic potential in gastric cancer.","date":"2000","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/11106237","citation_count":162,"is_preprint":false},{"pmid":"29069865","id":"PMC_29069865","title":"S100A4 in cancer progression and metastasis: A systematic review.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29069865","citation_count":156,"is_preprint":false},{"pmid":"8120097","id":"PMC_8120097","title":"Binding of pEL98 protein, an S100-related calcium-binding protein, to nonmuscle tropomyosin.","date":"1994","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/8120097","citation_count":153,"is_preprint":false},{"pmid":"18322670","id":"PMC_18322670","title":"S100A4: a common mediator of epithelial-mesenchymal transition, fibrosis and regeneration in diseases?","date":"2008","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/18322670","citation_count":153,"is_preprint":false},{"pmid":"9291441","id":"PMC_9291441","title":"Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma.","date":"1997","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9291441","citation_count":149,"is_preprint":false},{"pmid":"17466960","id":"PMC_17466960","title":"S100A4 is upregulated in injured myocardium and promotes growth and survival of cardiac myocytes.","date":"2007","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/17466960","citation_count":129,"is_preprint":false},{"pmid":"8968106","id":"PMC_8968106","title":"Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme.","date":"1996","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/8968106","citation_count":128,"is_preprint":false},{"pmid":"16002749","id":"PMC_16002749","title":"Interdependent serotonin transporter and receptor pathways regulate S100A4/Mts1, a gene associated with pulmonary vascular disease.","date":"2005","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/16002749","citation_count":125,"is_preprint":false},{"pmid":"9815629","id":"PMC_9815629","title":"Increased expression of S100A4, a metastasis-associated gene, in human colorectal adenocarcinomas.","date":"1997","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/9815629","citation_count":124,"is_preprint":false},{"pmid":"9920410","id":"PMC_9920410","title":"Calcium-binding protein S100A4 in health and disease.","date":"1998","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/9920410","citation_count":121,"is_preprint":false},{"pmid":"20519440","id":"PMC_20519440","title":"S100A4 regulates macrophage chemotaxis.","date":"2010","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/20519440","citation_count":118,"is_preprint":false},{"pmid":"12506178","id":"PMC_12506178","title":"Differential expression of S100A2 and S100A4 during progression of human prostate adenocarcinoma.","date":"2003","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/12506178","citation_count":112,"is_preprint":false},{"pmid":"9696040","id":"PMC_9696040","title":"Human S100A4 (p9Ka) induces the metastatic phenotype upon benign tumour cells.","date":"1998","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9696040","citation_count":104,"is_preprint":false},{"pmid":"3430604","id":"PMC_3430604","title":"Molecular cloning and sequence of the gene for p9Ka. A cultured myoepithelial cell protein with strong homology to S-100, a calcium-binding protein.","date":"1987","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/3430604","citation_count":103,"is_preprint":false},{"pmid":"34035222","id":"PMC_34035222","title":"Exosomal S100A4 derived from highly metastatic hepatocellular carcinoma cells promotes metastasis by activating STAT3.","date":"2021","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/34035222","citation_count":102,"is_preprint":false},{"pmid":"9703888","id":"PMC_9703888","title":"S100A4 (MTS1) calcium binding protein in cancer growth, invasion and metastasis.","date":"1998","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9703888","citation_count":94,"is_preprint":false},{"pmid":"30710284","id":"PMC_30710284","title":"The Multifaceted S100A4 Protein in Cancer and Inflammation.","date":"2019","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/30710284","citation_count":93,"is_preprint":false},{"pmid":"7928629","id":"PMC_7928629","title":"Involvement of S100-related calcium-binding protein pEL98 (or mts1) in cell motility and tumor cell invasion.","date":"1994","source":"Japanese journal of cancer research : Gann","url":"https://pubmed.ncbi.nlm.nih.gov/7928629","citation_count":92,"is_preprint":false},{"pmid":"17504119","id":"PMC_17504119","title":"Metastasis-associated protein S100A4: spotlight on its role in cell migration.","date":"2007","source":"Current cancer drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/17504119","citation_count":89,"is_preprint":false},{"pmid":"1384693","id":"PMC_1384693","title":"S100 alpha, CAPL, and CACY: molecular cloning and expression analysis of three calcium-binding proteins from human heart.","date":"1992","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1384693","citation_count":89,"is_preprint":false},{"pmid":"29204268","id":"PMC_29204268","title":"Role of metastasis-induced protein S100A4 in human non-tumor pathophysiologies.","date":"2017","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/29204268","citation_count":89,"is_preprint":false},{"pmid":"27331819","id":"PMC_27331819","title":"S100A4 in Cancer Metastasis: Wnt Signaling-Driven Interventions for Metastasis Restriction.","date":"2016","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/27331819","citation_count":84,"is_preprint":false},{"pmid":"16265347","id":"PMC_16265347","title":"S100A4 (Mts1) gene overexpression is associated with invasion and metastasis of papillary thyroid carcinoma.","date":"2005","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16265347","citation_count":83,"is_preprint":false},{"pmid":"28530639","id":"PMC_28530639","title":"Calcium-binding protein S100A4 confers mesenchymal progenitor cell fibrogenicity in idiopathic pulmonary fibrosis.","date":"2017","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/28530639","citation_count":79,"is_preprint":false},{"pmid":"19059703","id":"PMC_19059703","title":"Metastasis promoter S100A4 is a potentially valuable molecular target for cancer therapy.","date":"2008","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/19059703","citation_count":78,"is_preprint":false},{"pmid":"15452371","id":"PMC_15452371","title":"Expression of S100A4 and Met: potential predictors for metastasis and survival in early-stage breast cancer.","date":"2004","source":"Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/15452371","citation_count":76,"is_preprint":false},{"pmid":"21618579","id":"PMC_21618579","title":"Nuclear expression of S100A4 calcium-binding protein increases cholangiocarcinoma invasiveness and metastasization.","date":"2011","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/21618579","citation_count":73,"is_preprint":false},{"pmid":"11875708","id":"PMC_11875708","title":"S100A4 (p9Ka) protein in colon carcinoma and liver metastases: association with carcinoma cells and T-lymphocytes.","date":"2002","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11875708","citation_count":72,"is_preprint":false},{"pmid":"11527429","id":"PMC_11527429","title":"Binding to intracellular targets of the metastasis-inducing protein, S100A4 (p9Ka).","date":"2001","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11527429","citation_count":72,"is_preprint":false},{"pmid":"12439718","id":"PMC_12439718","title":"Expression of S100A4, E-cadherin, alpha- and beta-catenin in breast cancer biopsies.","date":"2002","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12439718","citation_count":71,"is_preprint":false},{"pmid":"15133476","id":"PMC_15133476","title":"Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma.","date":"2004","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/15133476","citation_count":69,"is_preprint":false},{"pmid":"32307910","id":"PMC_32307910","title":"Extracellular S100A4 as a key player in fibrotic diseases.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32307910","citation_count":67,"is_preprint":false},{"pmid":"10753920","id":"PMC_10753920","title":"Interaction in vivo and in vitro of the metastasis-inducing S100 protein, S100A4 (p9Ka) with S100A1.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10753920","citation_count":66,"is_preprint":false},{"pmid":"8204608","id":"PMC_8204608","title":"Purification and characterization of the recombinant human calcium-binding S100 proteins CAPL and CACY.","date":"1994","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8204608","citation_count":61,"is_preprint":false},{"pmid":"7822773","id":"PMC_7822773","title":"Immunocytochemical distribution of the calcium-binding protein p9Ka in normal rat tissues: variation in the cellular location in different tissues.","date":"1995","source":"The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society","url":"https://pubmed.ncbi.nlm.nih.gov/7822773","citation_count":60,"is_preprint":false},{"pmid":"6253076","id":"PMC_6253076","title":"The gross anatomy of a tRNA gene cluster at region 42A of the D. melanogaster chromosome.","date":"1980","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/6253076","citation_count":59,"is_preprint":false},{"pmid":"31124787","id":"PMC_31124787","title":"Cell non-autonomous functions of S100a4 drive fibrotic tendon healing.","date":"2019","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/31124787","citation_count":58,"is_preprint":false},{"pmid":"7954872","id":"PMC_7954872","title":"Cellular localization of pEL98 protein, an S100-related calcium binding protein, in fibroblasts and its tissue distribution analyzed by monoclonal antibodies.","date":"1994","source":"Cell structure and function","url":"https://pubmed.ncbi.nlm.nih.gov/7954872","citation_count":57,"is_preprint":false},{"pmid":"1731618","id":"PMC_1731618","title":"Isolation and characterization of a calcium-binding protein derived from mRNA termed p9Ka, pEL-98, 18A2, or 42A by the newly synthesized vasorelaxant W-66 affinity chromatography.","date":"1992","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/1731618","citation_count":56,"is_preprint":false},{"pmid":"8034656","id":"PMC_8034656","title":"Interactions in vitro of p9Ka, the rat S-100-related, metastasis-inducing, calcium-binding protein.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8034656","citation_count":56,"is_preprint":false},{"pmid":"25152734","id":"PMC_25152734","title":"NFAT5-mediated expression of S100A4 contributes to proliferation and migration of renal carcinoma cells.","date":"2014","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/25152734","citation_count":56,"is_preprint":false},{"pmid":"38627387","id":"PMC_38627387","title":"METTL14 downregulation drives S100A4+ monocyte-derived macrophages via MyD88/NF-κB pathway to promote MAFLD progression.","date":"2024","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/38627387","citation_count":55,"is_preprint":false},{"pmid":"29449540","id":"PMC_29449540","title":"S100A4 promotes lung tumor development through β-catenin pathway-mediated autophagy inhibition.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29449540","citation_count":51,"is_preprint":false},{"pmid":"19641515","id":"PMC_19641515","title":"Significance of the S100A4 protein in psoriasis.","date":"2010","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/19641515","citation_count":50,"is_preprint":false},{"pmid":"17688917","id":"PMC_17688917","title":"Expression of S100A2 and S100A4 predicts for disease progression and patient survival in bladder cancer.","date":"2007","source":"Urology","url":"https://pubmed.ncbi.nlm.nih.gov/17688917","citation_count":46,"is_preprint":false},{"pmid":"1512251","id":"PMC_1512251","title":"Calvasculin, an encoded protein from mRNA termed pEL-98, 18A2, 42A, or p9Ka, is secreted by smooth muscle cells in culture and exhibits Ca(2+)-dependent binding to 36-kDa microfibril-associated glycoprotein.","date":"1992","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1512251","citation_count":46,"is_preprint":false},{"pmid":"9570150","id":"PMC_9570150","title":"Expression of metastasis-associated genes h-mts1 (S100A4) and nm23 in carcinoma of breast is related to disease progression.","date":"1998","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/9570150","citation_count":45,"is_preprint":false},{"pmid":"17673926","id":"PMC_17673926","title":"Hypomethylation-induced expression of S100A4 in endometrial carcinoma.","date":"2007","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/17673926","citation_count":45,"is_preprint":false},{"pmid":"18781956","id":"PMC_18781956","title":"Metastasis-inducing S100A4 protein: implication in non-malignant human pathologies.","date":"2008","source":"Current molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18781956","citation_count":44,"is_preprint":false},{"pmid":"15608682","id":"PMC_15608682","title":"Mutually antagonistic actions of S100A4 and S100A1 on normal and metastatic phenotypes.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15608682","citation_count":44,"is_preprint":false},{"pmid":"25253987","id":"PMC_25253987","title":"S100A4 is upregulated in proliferative diabetic retinopathy and correlates with markers of angiogenesis and fibrogenesis.","date":"2014","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/25253987","citation_count":44,"is_preprint":false},{"pmid":"20070253","id":"PMC_20070253","title":"Functional interaction between Smad3 and S100A4 (metastatin-1) for TGF-beta-mediated cancer cell invasiveness.","date":"2010","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/20070253","citation_count":43,"is_preprint":false},{"pmid":"1890696","id":"PMC_1890696","title":"Differential regulation of S100 beta and mRNAs coding for S100-like proteins (42A and 42C) during development and after lesion of rat sciatic nerve.","date":"1991","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/1890696","citation_count":42,"is_preprint":false},{"pmid":"30083275","id":"PMC_30083275","title":"The S100A4 Protein Signals through the ErbB4 Receptor to Promote Neuronal Survival.","date":"2018","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/30083275","citation_count":40,"is_preprint":false},{"pmid":"33918416","id":"PMC_33918416","title":"S100A4 in the Physiology and Pathology of the Central and Peripheral Nervous System.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/33918416","citation_count":39,"is_preprint":false},{"pmid":"20712050","id":"PMC_20712050","title":"Expression of protein S100A4 is a predictor of recurrence in colorectal cancer.","date":"2010","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/20712050","citation_count":37,"is_preprint":false},{"pmid":"29789685","id":"PMC_29789685","title":"S100A4 protects mice from high-fat diet-induced obesity and inflammation.","date":"2018","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29789685","citation_count":36,"is_preprint":false},{"pmid":"30927479","id":"PMC_30927479","title":"Clinical relevance of circulating MACC1 and S100A4 transcripts for ovarian cancer.","date":"2019","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30927479","citation_count":35,"is_preprint":false},{"pmid":"8037774","id":"PMC_8037774","title":"Expression of a calcium binding protein pEL98 (mts1) during differentiation of human promyelocytic leukemia HL-60 cells.","date":"1994","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/8037774","citation_count":33,"is_preprint":false},{"pmid":"7898625","id":"PMC_7898625","title":"Overexpression of the 18A2/mts1 gene and down-regulation of the TIMP-2 gene in invasive human glioma cell lines in vitro.","date":"1994","source":"Neuropathology and applied neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/7898625","citation_count":33,"is_preprint":false},{"pmid":"7546288","id":"PMC_7546288","title":"Expression of the rat, S-100-related, calcium-binding protein gene, p9Ka, in transgenic mice demonstrates different patterns of expression between these two species.","date":"1995","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/7546288","citation_count":33,"is_preprint":false},{"pmid":"16297707","id":"PMC_16297707","title":"S100A4 regulates E-cadherin expression in oral squamous cell carcinoma.","date":"2005","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/16297707","citation_count":33,"is_preprint":false},{"pmid":"10906702","id":"PMC_10906702","title":"Metastasis-associated mts1 (S100A4) protein in the developing and adult central nervous system.","date":"2000","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/10906702","citation_count":33,"is_preprint":false},{"pmid":"32117590","id":"PMC_32117590","title":"S100A4 promotes hepatocellular carcinogenesis by intensifying fibrosis-associated cancer cell stemness.","date":"2020","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/32117590","citation_count":32,"is_preprint":false},{"pmid":"24795458","id":"PMC_24795458","title":"S100A4 and uric acid promote mesenchymal stromal cell induction of IL-10+/IDO+ lymphocytes.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24795458","citation_count":32,"is_preprint":false},{"pmid":"10738249","id":"PMC_10738249","title":"Localisation by in situ hybridisation of S100A4 (p9Ka) mRNA in primary human breast tumour specimens.","date":"2000","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10738249","citation_count":31,"is_preprint":false},{"pmid":"30221056","id":"PMC_30221056","title":"S100A4 promotes colon inflammation and colitis-associated colon tumorigenesis.","date":"2018","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/30221056","citation_count":30,"is_preprint":false},{"pmid":"28721450","id":"PMC_28721450","title":"Smad3 and Bmal1 regulate p21 and S100A4 expression in myocardial stromal fibroblasts via TNF-α.","date":"2017","source":"Histochemistry and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/28721450","citation_count":30,"is_preprint":false},{"pmid":"27387233","id":"PMC_27387233","title":"Extracellular S100A4 affects endothelial cell integrity and stimulates transmigration of A375 melanoma cells.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/27387233","citation_count":29,"is_preprint":false},{"pmid":"29556233","id":"PMC_29556233","title":"S100A4 Protects Myeloid-Derived Suppressor Cells from Intrinsic Apoptosis via TLR4-ERK1/2 Signaling.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29556233","citation_count":29,"is_preprint":false},{"pmid":"17032501","id":"PMC_17032501","title":"Expression of calcium-binding proteins S100A2 and S100A4 in Barrett's adenocarcinomas.","date":"2006","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/17032501","citation_count":29,"is_preprint":false},{"pmid":"9180153","id":"PMC_9180153","title":"Elevated expression of calcium-binding protein p9Ka is associated with increasing malignant characteristics of rat prostate carcinoma cells.","date":"1997","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9180153","citation_count":28,"is_preprint":false},{"pmid":"26734465","id":"PMC_26734465","title":"Functional profile of S100A4-deficient T cells.","date":"2015","source":"Immunity, inflammation and disease","url":"https://pubmed.ncbi.nlm.nih.gov/26734465","citation_count":28,"is_preprint":false},{"pmid":"27721024","id":"PMC_27721024","title":"S100A4 protects the myocardium against ischemic stress.","date":"2016","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/27721024","citation_count":28,"is_preprint":false},{"pmid":"38219976","id":"PMC_38219976","title":"S100A4 a classical DAMP as a therapeutic target in fibrosis.","date":"2024","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/38219976","citation_count":27,"is_preprint":false},{"pmid":"33031790","id":"PMC_33031790","title":"Overexpression of S100A4 protects retinal ganglion cells against retinal ischemia-reperfusion injury in mice.","date":"2020","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/33031790","citation_count":27,"is_preprint":false},{"pmid":"36078170","id":"PMC_36078170","title":"Pharmacological Inhibition of S100A4 Attenuates Fibroblast Activation and Renal Fibrosis.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36078170","citation_count":26,"is_preprint":false},{"pmid":"34118929","id":"PMC_34118929","title":"Targeting S100A4 with niclosamide attenuates inflammatory and profibrotic pathways in models of amyotrophic lateral sclerosis.","date":"2021","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/34118929","citation_count":26,"is_preprint":false},{"pmid":"33135065","id":"PMC_33135065","title":"Neutralization of S100A4 induces stabilization of atherosclerotic plaques: role of smooth muscle cells.","date":"2022","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/33135065","citation_count":25,"is_preprint":false},{"pmid":"27927689","id":"PMC_27927689","title":"S100A4 Elevation Empowers Expression of Metastasis Effector Molecules in Human Breast Cancer.","date":"2016","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27927689","citation_count":25,"is_preprint":false},{"pmid":"16431343","id":"PMC_16431343","title":"S100A4 (Mts1): is there any relation to the pathogenesis of rheumatoid arthritis?","date":"2005","source":"Autoimmunity reviews","url":"https://pubmed.ncbi.nlm.nih.gov/16431343","citation_count":24,"is_preprint":false},{"pmid":"23830916","id":"PMC_23830916","title":"Expression of metastasin S100A4 is essential for bone resorption and regulates osteoclast function.","date":"2013","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/23830916","citation_count":24,"is_preprint":false},{"pmid":"27348205","id":"PMC_27348205","title":"S100A4 accelerates the proliferation and invasion of endometrioid carcinoma and is associated with the \"MELF\" pattern.","date":"2016","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/27348205","citation_count":24,"is_preprint":false},{"pmid":"33315931","id":"PMC_33315931","title":"S100A4+ macrophages facilitate zika virus invasion and persistence in the seminiferous tubules via interferon-gamma mediation.","date":"2020","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/33315931","citation_count":24,"is_preprint":false},{"pmid":"29282275","id":"PMC_29282275","title":"S100A4 regulates macrophage invasion by distinct myosin-dependent and myosin-independent mechanisms.","date":"2017","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/29282275","citation_count":24,"is_preprint":false},{"pmid":"20855150","id":"PMC_20855150","title":"Small interfering RNA-directed knockdown of S100A4 decreases proliferation and invasiveness of osteosarcoma cells.","date":"2010","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/20855150","citation_count":24,"is_preprint":false},{"pmid":"9858899","id":"PMC_9858899","title":"Interleukin-1 alpha and basic fibroblast growth factor induction of matrix metalloproteinases and their inhibitors in osteosarcoma cells is modulated by the metastasis associated protein CAPL.","date":"1998","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9858899","citation_count":23,"is_preprint":false},{"pmid":"32084430","id":"PMC_32084430","title":"The protein S100A4 as a novel marker of insulin resistance in prepubertal and pubertal children with obesity.","date":"2020","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/32084430","citation_count":22,"is_preprint":false},{"pmid":"8119967","id":"PMC_8119967","title":"Purification and primary structure of Capl, an S-100-related calcium-binding protein isolated from bovine retina.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8119967","citation_count":21,"is_preprint":false},{"pmid":"32914661","id":"PMC_32914661","title":"Calcium-Binding Protein S100A4 Is Upregulated in Carotid Atherosclerotic Plaques and Contributes to Expansive Remodeling.","date":"2020","source":"Journal of the American Heart Association","url":"https://pubmed.ncbi.nlm.nih.gov/32914661","citation_count":21,"is_preprint":false},{"pmid":"38609357","id":"PMC_38609357","title":"ANXA9 facilitates S100A4 and promotes breast cancer progression through modulating STAT3 pathway.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/38609357","citation_count":20,"is_preprint":false},{"pmid":"30450809","id":"PMC_30450809","title":"Osterix promotes the migration and angiogenesis of breast cancer by upregulation of S100A4 expression.","date":"2018","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30450809","citation_count":20,"is_preprint":false},{"pmid":"19194111","id":"PMC_19194111","title":"Different expression and clinical role of S100A4 in serous ovarian carcinoma at different anatomic sites.","date":"2009","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19194111","citation_count":20,"is_preprint":false},{"pmid":"9242709","id":"PMC_9242709","title":"Transcriptional down-regulation of the metastasis-inducing S100A4 (p9Ka) in benign but not in malignant rat mammary epithelial cells by GC-factor.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9242709","citation_count":20,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49312,"output_tokens":8386,"usd":0.136863,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17975,"output_tokens":5218,"usd":0.110162,"stage2_stop_reason":"end_turn"},"total_usd":0.247025,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"S100A4 (pEL98) binds nonmuscle tropomyosin isoform 2 (TM2) in a Ca2+-dependent manner; the binding site was mapped to residues 39–107 on TM2, and some S100A4 co-localizes with nonmuscle tropomyosins in microfilament bundles of NIH 3T3 cells.\",\n      \"method\": \"GST pulldown with Ca2+-dependence assay, competition with free TM2, affinity chromatography, partial amino acid sequencing, immunofluorescence co-localization, cell fractionation (Triton-soluble vs. insoluble)\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with multiple orthogonal methods (pulldown, competition, fractionation, immunofluorescence) in a single rigorous study\",\n      \"pmids\": [\"8120097\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Recombinant rat S100A4 (p9Ka) forms multimers in vitro (not via disulfide bonds), binds 2 mol Ca2+/mol protein (antagonized by mono- and divalent cations), and binds to at least two intracellular polypeptides in mammary cell extracts. Immunofluorescence shows co-localization with actin filaments.\",\n      \"method\": \"Recombinant protein characterization, equilibrium dialysis, gel overlay / affinity binding assay, immunofluorescence\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with multiple methods (biochemical binding, Ca2+ measurement, immunofluorescence) in one rigorous study\",\n      \"pmids\": [\"8034656\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"S100A4 (calvasculin) is secreted by smooth muscle cells and fibroblasts in culture and binds the extracellular 36-kDa microfibril-associated glycoprotein (MAP) in a Ca2+-dependent manner; stoichiometry ~2.2 calvasculin/mol MAP.\",\n      \"method\": \"Immunofluorescence demonstrating granular (secretory) distribution, Ca2+-dependent solid-phase binding assay, stoichiometry analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct secretion demonstrated by immunofluorescence, binding confirmed by solid-phase assay with Ca2+ dependence, single lab\",\n      \"pmids\": [\"1512251\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"S100A4 (pEL98) expression level correlates with and is sufficient to promote cell motility and tumor cell invasiveness; transfection of pEL98 cDNA into low-motility cells directly increases motility.\",\n      \"method\": \"phagokinesis cell-track assay, cDNA transfection overexpression, Northern/Western blot correlation across cell lines\",\n      \"journal\": \"Japanese journal of cancer research : Gann\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function transfection with defined phenotypic readout (motility), supported by correlation across multiple cell lines, single lab\",\n      \"pmids\": [\"7928629\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Human S100A4 possesses metastasis-inducing capability: transfection into benign rat mammary Rama 37 cells induced metastasis in vivo only in clones expressing high levels of human S100A4, not in clones with undetectable expression.\",\n      \"method\": \"Gene transfection, in vivo metastasis assay in syngeneic rats, immunocytochemistry\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — gain-of-function in vivo assay replicated across multiple clones with dose-response relationship; confirms earlier rodent studies\",\n      \"pmids\": [\"9696040\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Expression of S100A4 in MMTV-neu transgenic mice cooperates with the Neu oncogene to induce macroscopic lung metastases; primary and secondary lesions express S100A4, particularly at invasion fronts.\",\n      \"method\": \"Transgenic mouse cross (MMTV-neu × S100A4 transgenic), macroscopic metastasis assessment, immunohistochemistry\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo transgenic gain-of-function demonstrating metastasis induction cooperating with an oncogene, histological verification\",\n      \"pmids\": [\"8895508\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Ribozyme-mediated knockdown of S100A4 (CAPL) reduces metastatic skeletal colonization of human osteosarcoma cells in vivo without affecting proliferation or tumorigenicity, establishing S100A4 as a direct determinant of metastatic potential.\",\n      \"method\": \"Hammerhead ribozyme transfection, 5'-RACE cleavage assay, intracardiac injection metastasis model in nude rats, in vivo/in vitro proliferation assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with verified mRNA cleavage, in vivo metastasis phenotype, proliferation controlled, single lab\",\n      \"pmids\": [\"8968106\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"S100A4 binds nonmuscle myosin and p53 (wild-type and mutant arg-175-his) with significant affinity by optical biosensor measurement; S100A4 shows greater affinity for p53 than for myosin. S100A4 does not interact with actin, tropomyosin, or tubulin under these conditions.\",\n      \"method\": \"Optical biosensor (surface plasmon resonance) binding assay with recombinant proteins\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct in vitro binding measurement with affinity quantification; negative controls (actin, tropomyosin, tubulin) included; single lab, single method\",\n      \"pmids\": [\"11527429\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"S100A4 interacts with S100A1 in vivo (detected by FRET in living cells) and in vitro (affinity chromatography, gel overlay); interaction is abolished by mutagenesis of conserved dimerization residues. S100A1 modulates S100A4's inhibition of nonmuscle myosin-A self-association and phosphorylation, reduces S100A4-induced motility and growth in soft agar, and attenuates metastasis in vivo.\",\n      \"method\": \"Yeast two-hybrid, site-directed mutagenesis, affinity chromatography, gel overlay, FRET in living cells, biosensor binding assay, in vitro myosin assay, soft agar assay, in vivo metastasis model\",\n      \"journal\": \"The Journal of biological chemistry / Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods (yeast two-hybrid, mutagenesis, FRET, in vitro myosin assay, in vivo) across two papers from the same lab\",\n      \"pmids\": [\"10753920\", \"15608682\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"S100A4 (calvasculin/CAPL) is a homodimeric Ca2+-binding protein with two low-affinity Ca2+-specific sites per homodimer (K0.5 ~0.15 mM, slightly cooperative); it does not form heterodimers with S100B (CACY) in vitro, and Ca2+ binding induces conformational changes.\",\n      \"method\": \"Recombinant protein expression/purification, equilibrium dialysis (flow dialysis), fluorescence spectroscopy\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — rigorous biochemical characterization of Ca2+-binding stoichiometry and cooperativity; single lab with multiple methods\",\n      \"pmids\": [\"8204608\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Serotonin (5-HT) elevates S100A4 mRNA and protein in human pulmonary artery smooth muscle cells via 5-HT1B receptor and SERT, requiring pERK1/2 nuclear translocation (dependent on SERT, MAO activity, and ROS) and subsequent pGATA-4-mediated transcription; secreted S100A4 then stimulates HPASMC proliferation and migration through RAGE.\",\n      \"method\": \"Cell culture, pharmacological inhibition (SB224289, fluoxetine), siRNA knockdown of SERT, qPCR, ELISA, proliferation/migration assays\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic dissection of transcriptional pathway with multiple pharmacological inhibitors and siRNA, single lab\",\n      \"pmids\": [\"16002749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"S100A4 protein is upregulated in hypertrophic and infarcted rat and human hearts; recombinant S100A4 elicits hypertrophic response and promotes survival (anti-apoptotic) in cardiac myocyte cultures, with ERK1/2 activation required for both hypertrophy and survival effects.\",\n      \"method\": \"qRT-PCR, immunoblotting, confocal microscopy/fractionation, recombinant protein treatment, ERK1/2 inhibition, viability assays\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro recombinant protein treatment with pathway inhibition, confirmed by human/rat tissue localization; single lab\",\n      \"pmids\": [\"17466960\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"S100A4 is required for macrophage chemotaxis and recruitment to inflammation sites in vivo; S100A4-deficient bone marrow macrophages form unstable protrusions, overassemble myosin-IIA, and exhibit altered CSF-1 receptor signaling.\",\n      \"method\": \"S100A4 gene-targeted knockout mice, in vivo peritoneal recruitment assay, in vitro chemotaxis assay, myosin assembly analysis, receptor signaling assays\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean knockout model with defined in vivo and in vitro phenotypes, mechanistic link to myosin-IIA overassembly and CSF-1R signaling\",\n      \"pmids\": [\"20519440\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"S100A4 regulates macrophage invasion through two mechanistically distinct pathways: (1) a myosin-IIA-dependent defect in podosome rosette-mediated matrix degradation and (2) a myosin-independent increase in microtubule acetylation that increases podosome rosette stability and inhibits invasion.\",\n      \"method\": \"S100A4-/- bone marrow macrophages, podosome rosette imaging, matrix degradation assay, myosin-IIA manipulation, microtubule acetylation measurement\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mechanistically resolved two independent pathways using S100A4-/- cells with multiple orthogonal readouts; replication from same group extending prior knockout study\",\n      \"pmids\": [\"29282275\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"S100A4 physically and functionally interacts with Smad3 in a Ca2+-dependent manner; the S100A4-binding site is in the N-terminal region of Smad3. S100A4 potentiates Smad3 (and Smad2) transcriptional activity and increases TGF-β-induced MMP-9 expression and cell invasion; siRNA depletion reverses these effects.\",\n      \"method\": \"Co-immunoprecipitation, Ca2+-dependence assay, reporter assay for Smad transcriptional activity, siRNA knockdown, MMP-9 ELISA, Boyden chamber invasion assay\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with Ca2+-dependence plus functional gain/loss-of-function validation, single lab\",\n      \"pmids\": [\"20070253\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In IPF mesenchymal progenitor cells, nuclear S100A4 interacts with L-isoaspartyl methyltransferase to promote p53 degradation and MPC self-renewal; S100A4 gain-of-function confers fibrogenic properties to non-IPF MPCs, and S100A4 is required for conversion of a self-limited to persistent bleomycin fibrosis model in vivo.\",\n      \"method\": \"Ex vivo analysis of IPF MPCs, co-IP of S100A4 with L-isoaspartyl methyltransferase, p53 degradation assay, S100A4 overexpression in non-IPF MPCs, in vivo bleomycin mouse model with human MPC injection\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP identifying interaction partner, in vivo loss- and gain-of-function, multiple orthogonal methods in single rigorous study\",\n      \"pmids\": [\"28530639\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Extracellular S100A4 inhibits autophagy and promotes tumor cell proliferation via RAGE receptor, acting through the Wnt/β-catenin pathway; RAGE-specific inhibition abolishes S100A4-mediated autophagy suppression. S100A4-deficient mice show retarded lung tumor development with increased autophagy markers.\",\n      \"method\": \"S100A4 overexpression/siRNA knockdown, autophagy markers (LC3-II), β-catenin measurement, RAGE inhibitor (FPS-ZM1), S100A4-/- mouse tumor model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway dissected with pharmacological RAGE inhibition and KO mice plus in vitro gain/loss-of-function; single lab\",\n      \"pmids\": [\"29449540\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"S100A4 protects myeloid-derived suppressor cells from intrinsic apoptosis via TLR4/ERK1/2 signaling-dependent caspase-9 inhibition; S100A4-/- mice have reduced peripheral MDSCs and spontaneously reject tumors.\",\n      \"method\": \"S100A4-/- tumor models, MDSC isolation and apoptosis assays, TLR4 and ERK1/2 pathway analysis, caspase-9 activity measurement\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined molecular pathway (TLR4-ERK1/2-caspase-9) in KO model with tumor model phenotype, single lab\",\n      \"pmids\": [\"29556233\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"S100A4 controls PPAR-γ upregulation in macrophages, which is required for FAO induction during M2-like protumor polarization; S100A4-deficient TAMs fail to upregulate PPAR-γ-dependent CD36, reducing FA absorption and FAO, and thereby lose protumor activity.\",\n      \"method\": \"Macrophage-specific S100A4-KO mice, whole-body KO mice, IL-4 stimulation, RNA-seq, flow cytometry, Western blot, FAO measurement, FA uptake assay\",\n      \"journal\": \"Journal for immunotherapy of cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mechanistic pathway (S100A4→PPAR-γ→CD36→FAO) established with cell-specific KO, multiple metabolic and molecular readouts, in vivo tumor models\",\n      \"pmids\": [\"34145030\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Exosomal S100A4 from highly metastatic HCC cells activates STAT3 phosphorylation in recipient low-metastatic cells, inducing osteopontin (OPN) transcription and promoting metastasis in vitro and in vivo.\",\n      \"method\": \"Exosome isolation, iTRAQ mass spectrometry, in vitro invasion/migration assays, xenograft in vivo metastasis, STAT3 phosphorylation assay, OPN promoter analysis\",\n      \"journal\": \"Signal transduction and targeted therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic pathway (exosomal S100A4→STAT3 phosphorylation→OPN) validated in vitro and in vivo, single lab\",\n      \"pmids\": [\"34035222\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"S100A4 interacts with Smad3 to stabilize the Smad3/Smad4 complex and promote their nuclear translocation, thereby facilitating TGF-β1-induced fibroblast activation; pharmacological inhibition with niclosamide reduces this interaction and attenuates renal fibrosis in vivo.\",\n      \"method\": \"Co-IP (S100A4–Smad3 interaction), Smad3/Smad4 complex stability assay, nuclear translocation assay, S100A4 overexpression/knockdown in renal fibroblasts, folic acid nephropathy mouse model, niclosamide treatment\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — Co-IP identifying specific molecular interaction, mechanistic nuclear translocation assay, gain/loss-of-function, in vivo model; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"36078170\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Extracellular oligomeric S100A4 induces NF-κB activation and, together with PDGF-BB, drives smooth muscle cell phenotypic transition to a pro-inflammatory synthetic phenotype via toll-like receptor-4; neutralization of extracellular S100A4 in a mouse atherosclerosis model decreases plaque area, necrotic core, and macrophage content while increasing contractile markers.\",\n      \"method\": \"Recombinant oligomeric S100A4 treatment of SMCs, NF-κB reporter assay, RNA-seq, TLR4 signaling assay, ApoE-/- atherosclerosis mouse model with neutralizing antibody\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic pathway (oS100A4→TLR4→NF-κB→phenotype transition) established with RNA-seq and in vivo neutralization; multiple methods, single lab\",\n      \"pmids\": [\"33135065\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"S100A4 neuroprotection involves signaling through ErbB4 and its ligand Neuregulin-1: neuroprotective effect requires ErbB4 expression and ErbB2/Akt signaling, and is reduced by functional blockade of NRG/ErbB4. S100A4 also binds ErbB1 (EGFR) and ErbB3.\",\n      \"method\": \"ErbB4 knockdown/overexpression, pharmacological ErbB blockade, binding assays, primary and immortalized dopaminergic neuron cell death models\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined receptor pathway with genetic (knockdown) and pharmacological validation; binding to ErbB1/ErbB3 shown; single lab\",\n      \"pmids\": [\"30083275\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"S100A4 elevation in Drosophila promotes metastatic dissemination of RasV12-induced tumors via activation of the stress kinase JNK and upregulation of MMP1; genetic and chemical blockade of JNK or MMP1 suppresses S100A4-mediated metastasis in this model.\",\n      \"method\": \"Drosophila genetic model (RasV12 + S100A4 overexpression), JNK reporter assay, MMP1 measurement, genetic epistasis (loss-of-function of JNK and MMP1)\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis in a model organism with pathway placement (JNK–MMP1); single lab\",\n      \"pmids\": [\"27927689\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"S100A4 deficiency increases trabecular and cortical bone mass in mice; S100A4-deficient osteoclasts are small with few nuclei and pseudopodial processes, have low surface integrins, poor adhesion capacity, impaired multinucleation, and low cathepsin K and MMP3/MMP9 content, indicating S100A4 is required for functional osteoclastogenesis and bone resorption.\",\n      \"method\": \"S100A4-KO mice, shRNA lentiviral knockdown, pQCT, histomorphometry, TRAP staining, osteoclast differentiation assay, integrin surface expression\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two independent loss-of-function approaches (KO and shRNA) with defined cellular and molecular phenotypes; multiple orthogonal readouts\",\n      \"pmids\": [\"23830916\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"S100A4 drives fibrotic tendon healing primarily through a cell non-autonomous (paracrine/secreted) mechanism; S100A4 haploinsufficiency decreases myofibroblast and macrophage content at injury sites; S100a4-lineage cells become α-SMA+ myofibroblasts via loss of S100a4 expression; antagonism of its putative receptor RAGE also decreases scar formation.\",\n      \"method\": \"S100a4 haploinsufficient mice, lineage tracing (S100a4-Cre), RAGE antagonist treatment, immunofluorescence quantification of myofibroblasts and macrophages, biomechanical tendon testing\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — combination of genetic mouse models (haploinsufficiency + lineage tracing), small molecule inhibition, and functional biomechanical readout\",\n      \"pmids\": [\"31124787\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"NFAT5 transcriptionally induces S100A4 expression in renal carcinoma cells; siRNA-mediated knockdown of NFAT5 reduces S100A4 levels and is accompanied by decreased proliferation and migration of CaKi-1 cells.\",\n      \"method\": \"NFAT5 siRNA knockdown, reporter assay for NFAT5 activity, qPCR for S100A4, proliferation and migration assays\",\n      \"journal\": \"Frontiers in physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — siRNA loss-of-function with clear transcriptional link; single lab, single method for the S100A4 regulatory relationship\",\n      \"pmids\": [\"25152734\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"S100A4 protects cardiac myocytes against ischemic injury; cardiac myocyte-specific overexpression protects infarcted myocardium, while S100A4 KO worsens outcomes with increased apoptosis, fibrosis, and reduced capillary density. S100A4 promotes survival through AKT signaling and VEGF expression.\",\n      \"method\": \"S100A4 KO mice, cardiac myocyte-specific S100A4 overexpression transgenic mice, myocardial infarction model, apoptosis assays, Western blot (AKT phosphorylation), VEGF measurement\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal KO and tissue-specific overexpression with defined molecular mechanism (AKT/VEGF), multiple orthogonal readouts\",\n      \"pmids\": [\"27721024\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"A GC-factor binding sequence ~1,300 bp upstream of the S100A4 transcription start site acts as a cis-acting transcriptional repressor in benign mammary cells (low S100A4) but not in malignant/metastatic cells (high S100A4); GC-factor mRNA levels are inversely correlated with S100A4 mRNA across mammary cell lines.\",\n      \"method\": \"Reporter gene assay, Northern blot correlation across cell lines, identification of cis-acting element\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assay with defined cis-element plus mRNA correlation across cell lines; single lab\",\n      \"pmids\": [\"9242709\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Nuclear (but not cytoplasmic) expression of S100A4 in cholangiocarcinoma cells increases invasiveness and metastasization; siRNA silencing of S100A4 reduces motility, invasiveness, and MMP-9 secretion without affecting proliferation in EGI-1 CCA cells.\",\n      \"method\": \"siRNA knockdown, wound healing assay, Boyden chamber invasion assay, MMP-9 zymography, xenotransplantation in SCID mice with luciferase imaging, immunohistochemistry\",\n      \"journal\": \"Hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function (siRNA) with multiple functional readouts and in vivo xenograft validation, nuclear localization mechanistically specified\",\n      \"pmids\": [\"21618579\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Extracellular S100A4 interacts with RAGE on endothelial cells to reduce endothelial integrity (decreased TEER, reduced occludin and VE-cadherin expression) and facilitates transmigration of melanoma cells; this prometastatic effect is reduced by soluble RAGE (sRAGE).\",\n      \"method\": \"TEER measurement, Western blot for junction proteins, RAGE inhibition with sRAGE, transgenic A375 cell transmigration assay, intracardiac mouse metastasis model\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional RAGE-dependence established with sRAGE inhibition and in vivo model; single lab\",\n      \"pmids\": [\"27387233\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"S100A4 co-immunoprecipitates with RAGE in diabetic rat retinas; TNF-α (but not VEGF) induces upregulation of S100A4 in human retinal microvascular endothelial cells.\",\n      \"method\": \"Co-immunoprecipitation, Western blot, ELISA, immunohistochemistry, in vitro cytokine stimulation\",\n      \"journal\": \"Molecular vision\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single Co-IP in tissue extract, single lab, limited mechanistic follow-up\",\n      \"pmids\": [\"25253987\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"S100A4 modulates expression of matrix metalloproteinases (MMPs) and TIMPs in osteosarcoma cells: high-CAPL-expressing cells fail to upregulate MMP-1 and MMP-9 in response to bFGF or IL-1α, and high CAPL in synergy with IL-1α reduces TIMP-1 synthesis.\",\n      \"method\": \"Ribozyme-mediated CAPL knockdown cell lines, ELISA for MMP/TIMP levels, gelatin zymography, growth factor/cytokine stimulation\",\n      \"journal\": \"Anticancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — defined MMP/TIMP regulatory phenotype using loss-of-function cells with cytokine stimulation; single lab\",\n      \"pmids\": [\"9858899\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"S100A4 promotes hepatocellular carcinoma stemness synergistically with collagen I via RAGE and β-catenin signaling; this synergy requires both S100A4 and collagen I for maximal tumor sphere formation in vitro and tumor growth in vivo.\",\n      \"method\": \"S100A4-/- mouse hepatocarcinogenesis model (DEN/CCl4), tumor sphere formation assay, RAGE inhibition, β-catenin pathway analysis, in vivo tumor growth\",\n      \"journal\": \"Oncoimmunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined cooperative mechanism with extracellular matrix and receptor (RAGE/β-catenin) in KO model plus in vitro; single lab\",\n      \"pmids\": [\"32117590\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"S100A4 is a dimeric, Ca2+-binding EF-hand protein that operates both intracellularly—binding nonmuscle myosin-IIA, p53, Smad3, S100A1, and tropomyosin to regulate cell motility, cytoskeletal dynamics, apoptosis, and transcription—and extracellularly after secretion, where it signals through RAGE and TLR4 to activate NF-κB, promote SMC phenotypic transition, stimulate angiogenesis, and drive fibrosis and metastasis across multiple tissue contexts.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"S100A4 is a small, homodimeric EF-hand protein that binds two Ca2+ ions per monomer with low affinity and cooperativity, undergoing a Ca2+-induced conformational change but not heterodimerizing with S100B [#9, #1]. Intracellularly, it acts on the cytoskeleton through Ca2+-dependent association with nonmuscle tropomyosin and with nonmuscle myosin-IIA, with which it co-localizes in microfilament structures [#0, #7]; binding to myosin-IIA limits filament self-assembly, and this activity is modulated by heterocomplex formation with S100A1 [#8]. Through control of myosin-IIA dynamics S100A4 governs cell motility and protrusion stability, driving macrophage chemotaxis, podosome-mediated matrix degradation, and invasion [#3, #12, #13]. S100A4 is a direct determinant of metastatic potential: gain-of-function transfection induces metastasis and cooperates with the Neu oncogene in vivo, while ribozyme or siRNA depletion suppresses metastatic colonization and MMP-9-dependent invasion [#4, #5, #6, #29]. It additionally functions as a nuclear and transcriptional cofactor, binding p53 and the L-isoaspartyl methyltransferase to promote p53 degradation, and binding Smad3 in a Ca2+-dependent manner to stabilize the Smad3/Smad4 complex, potentiate TGF-β signaling, and drive fibroblast activation and fibrosis [#7, #15, #14, #20]. Upon secretion, extracellular S100A4 signals chiefly through the RAGE and TLR4 receptors to activate NF-κB, STAT3, AKT, ERK1/2, and Wnt/β-catenin pathways, thereby promoting smooth muscle phenotypic transition, angiogenesis, autophagy suppression, cell survival, and tissue fibrosis across vascular, cardiac, pulmonary, renal, and tendon contexts [#21, #16, #19, #27, #25, #10]. Its expression is set by transcriptional inputs including a GC-factor repressor element, NFAT5, and serotonin-driven GATA-4 signaling [#28, #26, #10].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Establishing that S100A4 is actively secreted answered whether this intracellular protein has an extracellular life, opening the door to receptor-mediated signaling models.\",\n      \"evidence\": \"Immunofluorescence of secretory distribution and Ca2+-dependent solid-phase binding to microfibril-associated glycoprotein in smooth muscle cells and fibroblasts\",\n      \"pmids\": [\"1512251\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No receptor identified at this stage\", \"Functional consequence of secretion not addressed\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Biochemical characterization defined S100A4 as a low-affinity Ca2+-binding homodimer that does not heterodimerize with S100B, establishing it as a distinct Ca2+ sensor whose targets change with Ca2+ occupancy.\",\n      \"evidence\": \"Recombinant protein, equilibrium/flow dialysis, fluorescence spectroscopy, multimerization analysis\",\n      \"pmids\": [\"8204608\", \"8034656\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological Ca2+ thresholds in cells unresolved\", \"Identity of intracellular target polypeptides not defined here\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Identifying tropomyosin and actin co-localization gave the first cytoskeletal targets, framing S100A4 as a Ca2+-dependent regulator of the actomyosin system.\",\n      \"evidence\": \"GST pulldown with mapped TM2 binding site, competition, fractionation, and immunofluorescence in NIH 3T3 cells\",\n      \"pmids\": [\"8120097\", \"8034656\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional effect of tropomyosin binding on filaments untested\", \"Later SPR found no direct actin/tropomyosin binding, indicating context dependence\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Demonstrating that S100A4 expression is sufficient to promote motility connected the cytoskeletal binding activity to a metastasis-relevant phenotype.\",\n      \"evidence\": \"Phagokinesis track assay with cDNA overexpression and cross-cell-line correlation\",\n      \"pmids\": [\"7928629\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular intermediary between S100A4 and motility not defined\", \"In vivo relevance not yet tested\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"In vivo transfection and oncogene-cooperation studies established S100A4 as a causal metastasis-inducing gene rather than a correlate.\",\n      \"evidence\": \"Gene transfection into benign rat mammary cells with dose-dependent in vivo metastasis; MMTV-neu transgenic cross\",\n      \"pmids\": [\"9696040\", \"8895508\", \"8968106\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism distinguishing high- vs low-expressing clones unresolved\", \"Did not separate intracellular from secreted contributions\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Direct affinity measurements identified myosin and p53 as preferred S100A4 partners, shifting the model toward both cytoskeletal and transcriptional/apoptotic regulation.\",\n      \"evidence\": \"Surface plasmon resonance with recombinant proteins and negative controls (actin, tropomyosin, tubulin)\",\n      \"pmids\": [\"11527429\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cellular consequence of p53 binding not addressed\", \"Discrepancy with earlier tropomyosin/actin binding unexplained\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Discovering the S100A4–S100A1 heterocomplex revealed an endogenous brake on S100A4's myosin-modulating and metastatic activities.\",\n      \"evidence\": \"Yeast two-hybrid, dimerization-residue mutagenesis, FRET in living cells, in vitro myosin assay, soft agar and in vivo metastasis assays\",\n      \"pmids\": [\"10753920\", \"15608682\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Regulation of heterocomplex formation in vivo unknown\", \"Stoichiometry in cells not defined\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Defining the serotonin/5-HT1B/SERT/ERK/GATA-4 axis explained how S100A4 transcription is induced and linked it to autocrine RAGE signaling in pulmonary vascular cells.\",\n      \"evidence\": \"Pharmacological inhibition, SERT siRNA, qPCR, ELISA, proliferation/migration assays in HPASMCs\",\n      \"pmids\": [\"16002749\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct GATA-4 binding to the S100A4 promoter not shown\", \"RAGE engagement inferred pharmacologically\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Knockout macrophage studies mechanistically tied S100A4 loss to myosin-IIA overassembly and defective chemotaxis, grounding its motility role in a defined cell type and target.\",\n      \"evidence\": \"S100A4-/- bone marrow macrophages, in vivo recruitment, chemotaxis and myosin assembly assays\",\n      \"pmids\": [\"20519440\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CSF-1R signaling alteration mechanism incomplete\", \"Intracellular vs secreted contribution to recruitment not separated\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identification of Ca2+-dependent Smad3 binding established S100A4 as a TGF-β pathway amplifier driving MMP-9 expression and invasion.\",\n      \"evidence\": \"Co-IP with Ca2+-dependence, Smad reporter assays, siRNA, MMP-9 ELISA, Boyden chamber invasion\",\n      \"pmids\": [\"20070253\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of Smad3 N-terminal binding not resolved\", \"Single-lab Co-IP without reciprocal genetic validation\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Bone phenotyping showed S100A4 is required for functional osteoclastogenesis, extending its motility/adhesion role to physiological bone remodeling.\",\n      \"evidence\": \"S100A4-KO mice and shRNA knockdown with pQCT, histomorphometry, TRAP and differentiation assays\",\n      \"pmids\": [\"23830916\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether effect is intracellular or secreted not resolved\", \"Receptor mediating osteoclast effects not identified\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Cross-species and cardiac/endothelial studies placed S100A4 in stress-kinase and survival signaling, defining MMP1/JNK, AKT/VEGF, and RAGE-dependent barrier disruption as downstream effectors.\",\n      \"evidence\": \"Drosophila JNK/MMP1 epistasis; cardiac KO and myocyte-specific overexpression with MI models; endothelial TEER and sRAGE inhibition with intracardiac metastasis\",\n      \"pmids\": [\"27927689\", \"27721024\", \"27387233\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Context-specific switch between pro-survival and pro-metastatic outputs unexplained\", \"Receptor coupling to AKT vs JNK not unified\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Resolving two independent macrophage invasion pathways and a nuclear S100A4–methyltransferase–p53 axis clarified that S100A4 acts through both myosin-dependent and myosin-independent and nuclear mechanisms.\",\n      \"evidence\": \"S100A4-/- macrophage podosome and microtubule acetylation assays; IPF MPC co-IP with L-isoaspartyl methyltransferase, p53 degradation, gain-of-function, bleomycin in vivo model\",\n      \"pmids\": [\"29282275\", \"28530639\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How microtubule acetylation is controlled by S100A4 mechanistically unknown\", \"Direct enzymatic link between the methyltransferase and p53 stability not fully defined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Receptor-resolved studies established RAGE/Wnt-β-catenin, TLR4/ERK/caspase-9, and NRG/ErbB4 as distinct extracellular S100A4 signaling routes controlling autophagy, immune-cell survival, and neuroprotection.\",\n      \"evidence\": \"RAGE inhibitor (FPS-ZM1) and KO autophagy tumor model; TLR4/ERK1/2 MDSC apoptosis in KO mice; ErbB4 knockdown/blockade in dopaminergic neuron models\",\n      \"pmids\": [\"29449540\", \"29556233\", \"30083275\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Which receptor dominates in a given tissue not defined\", \"Binding affinities to ErbB1/3/4 not quantified relative to RAGE/TLR4\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Mechanistic dissection in fibrosis, atherosclerosis, and HCC unified S100A4's secreted role: oligomeric S100A4 signals via TLR4/NF-κB and RAGE to drive SMC phenotype switching, fibroblast activation through Smad3/Smad4 stabilization, and metastatic niche formation via exosomal STAT3/OPN.\",\n      \"evidence\": \"Oligomeric S100A4 + PDGF-BB on SMCs with NF-κB reporter and ApoE-/- neutralization; S100A4–Smad3 Co-IP with niclosamide in folic-acid nephropathy; exosomal S100A4 STAT3/OPN in HCC xenografts\",\n      \"pmids\": [\"33135065\", \"36078170\", \"34035222\", \"34145030\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Oligomeric state required for receptor engagement in vivo not fully defined\", \"Whether the same secreted pool drives Smad3 stabilization and TLR4 signaling unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how a single Ca2+-binding protein partitions between distinct intracellular partners (myosin-IIA, p53, Smad3) and multiple extracellular receptors (RAGE, TLR4, ErbB family) to produce context-specific outcomes.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model reconciling diverse partner binding to the dimer\", \"Mechanism and regulation of S100A4 secretion not defined\", \"Receptor selectivity by oligomeric state untested side by side\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [0, 7, 8, 12]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [14, 15, 20]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [8, 14, 20]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [21, 16, 30]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [15, 29]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [2, 21, 25]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [12, 7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [21, 16, 19, 27]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [4, 5, 6, 15, 25]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [12, 17, 18]},\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [14, 29, 32]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"MYH9\", \"TPM2\", \"TP53\", \"SMAD3\", \"S100A1\", \"AGER\", \"TLR4\", \"ERBB4\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}